John M. Fahrenholz, MD, Vanderbilt University Medical Center, Nashville, Tennessee, discusses questions about nonadvanced systemic mastocytosis submitted by participants. Topics include triggers for mast cell activation, management strategies in the perioperative setting, diagnosis with consideration for hereditary alpha tryptasemia, and the optimal timing for the addition of avapritinib to the chosen therapies.
In this detailed webinar on systemic mastocytosis, Dr. Miti introduces Professor Prithviraj Bose, an expert in the field, who discusses the complexities of diagnosing and managing systemic mastocytosis…
Systemic mastocytosis with associated hematologic neoplasm (SM-AHN) presents unique diagnostic and treatment challenges. In this Medscape-certified activity, experts discuss the complex patient journey, from delayed diagnosis to individualized…
In an interview conducted at the 2024 American Society of Hematology Annual Meeting in San Diego, California, Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center,…
In an expert roundtable discussion, Matthew P. Giannetti, MD, Harvard Medical School, Brigham and Women’s Hospital Mastocytosis Center, Boston, Massachusetts; Lauren M. Madigan, MD, University of Utah, University…